

K073647

MPATHY MEDICAL DEVICES, LTD.
MINITAPE* EXTRA URETHRAL SLING
SPECIAL 510(k) NOTIFICATION

MAR - 3 2008

510(k) SUMMARY OF SAFETY & EFFECTIVENESS

SUBMITTER	Mpathy Medical Devices, Ltd. Glasgow – United Kingdom
CONTACT PERSON	Louis J. Mazzaresse U.S. Agent for Mpathy Medical Devices Ltd
DATE PREPARED	December 18, 2007
CLASSIFICATION	Surgical Mesh; ref. 21 CFR 878.3300 Class II
COMMON NAME	Urethral Sling
PROPRIETARY NAME	Minitape* Extra Urethral Sling
PREDICATE DEVICE	K023898 - Minitape RP™ Urethral Sling (Mpathy Medical Devices) K020007 - SAFYRE Sling (Corniche, LLC) K021263 - SPARC Sling System (American Medical Systems)
DEVICE DESCRIPTION	The subject device is a totally disposable mesh tape intended to be used as a pubourethral sling for the treatment of female urinary incontinence resulting from urethral hypermobility and/or intrinsic sphincter deficiency. It consists of a monocomponent polypropylene tape with integral fixation zones on either side of a central sling. These fixation zones at the ends of the tape anchor the sling to surrounding soft tissues.
TESTING	The device has been subjected to in-vitro and in-vivo testing which demonstrate the ability of the device to adequately restrain urethral tissue under conditions in excess of those encountered during normal clinical use.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

Mr. Louis J. Mazzaresse
U.S. Agent for Mpathy Medical Devices, Ltd.
Mpathy Medical Devices, Ltd.
24 Barberry Lane
MADISON CT 06443

SEP 28 2012

Re: K073647
Trade/Device Name: Modified Minitape* Extra Urethral Sling
Regulation Number: 21 CFR 878.3300
Regulation Name: Surgical mesh
Regulatory Class: II
Product Code: OTN
Dated: February 11, 2008
Received: February 13, 2008

Dear Mr. Mazzaresse:

This letter corrects our substantially equivalent letter of March 3, 2008.

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Benjamin R. Fisher". The signature is fluid and cursive, with the first name "Benjamin" being the most prominent part.

Benjamin R. Fisher, Ph.D.
Director
Division of Reproductive, Gastro-Renal,
and Urological Devices
Office of Device Evaluation
Center for Devices and Radiological Health

Enclosure

MPATHY MEDICAL DEVICES, LTD.
MINITAPE* EXTRA URETHRAL SLING
SPECIAL 510(K) NOTIFICATION

STATEMENT FOR INDICATIONS FOR USE

510(k) Number: K073647


Device Name: Minitape* Extra Urethral Sling

Indications for Use: The Minitape* Extra Urethral Sling is indicated for the surgical treatment of urodynamically proven female urinary stress incontinence resulting from urethral hypermobility and/or intrinsic sphincter deficiency

Prescription Use: Yes

DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED

Concurrence of CDRH, Office of Device Evaluation



(Division Sign-Off)
Division of General, Restorative,
and Neurological Devices

510(k) Number K073647